Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL: Pneumosil vs Typbar TCV in Children with Severe Acute Malnutrition
NCT06817421Phase 4Recruiting
- Start
- Jan 2026
- Primary completion
- Mar 2028
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of SIILPCV10 in pneumococcal disease, pneumococcal infection and pneumonia (2 arms). Primary endpoint: Serotype-specific immunoglobulin G (IgG) antibodies at 4 weeks. Started Jan 2026; status: recruiting.
02
Drugs
SIILPCV10
03
Conditions
pneumococcal diseasepneumococcal infectionpneumonia
Beyond the preview
Go deeper on NCT06817421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06817421.